MS Speaks

This is a long and complex article and is provided here only because one of the drugs that received negative recommendations was ozanimod. Table 4 shows ozanimod listed as a drug of "uncertain clinical benefit" according the assessments by CADTH (Canadian Agencies for Drugs and Technologies in Health) and NICE (UK National Institute for Health and Care Excellence).


From JAMA Internal Medicine (February 13, 2023)--"Assessment of FDA-approved drugs not recommended for use or reimbursement in other countries, 2017-2020":


http://bit.ly/3MyqDer[size=78%]http://bit.ly/3MyqDer[/size]